Sienna Cancer Diagnostics Limited has entered into an agreement with VivaZome Therapeutics Pty Ltd. ("VivaZome") to assist in the development of a commercial and scalable purification process for VivaZome's exosome-based therapies. This will be the first potential therapeutic application of Sienna's capture technology, EXO-NETTM. Sienna will provide EXO-NET beads which rapidly and specifically capture exosomes, potentially enabling the development of a commercial purification process for exosomes used in treatment therapies. Exosomes are small particles released by cells. They are a key effector in communication between cells and have the potential to become an off-the-shelf medicine without the technical problems of cell therapies. VivaZome is developing a large-scale, advanced manufacturing process for exosome production and purification, and needs a highly efficient method for separation and concentration of exosomes in cell culture supernatant. Sienna's EXO-NET platform has the potential to fufill this important step in the commercial development of therapeutic exosomes.